Anzeige
Mehr »
Login
Mittwoch, 08.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
GameStop 2.0? ...alle Anzeichen für den nächsten großen Short Squeeze!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40TUW | ISIN: CA36118K1084 | Ticker-Symbol: S0J
Frankfurt
08.01.25
21:32 Uhr
0,360 Euro
+0,045
+14,29 %
Branche
Rohstoffe
Aktienmarkt
Sonstige
1-Jahres-Chart
FUTURE FUELS INC Chart 1 Jahr
5-Tage-Chart
FUTURE FUELS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,3020,31422:09
ACCESSWIRE
288 Leser
Artikel bewerten:
(1)

Future Fuels Inc. Announces Changes to its Board of Directors & Grants Stock Options

Finanznachrichten News

VANCOUVER, BC / ACCESSWIRE / January 7, 2025 / Future Fuels Inc. (the "Company" or "Future Fuels") (TSXV:FTUR)(FWB:S0J) is pleased to announce the appointment Bernd Christmas and Mark Riccio to its board of directors.

Mr. Christmas is a highly esteemed legal professional and advocate for First Nations across Canada, recognized for his extensive experience and unwavering dedication to his field. As of February 1, 2024, he has taken on the role of Senior Counsel at JFK Law. He is situated at JFK Law's Six Nations office in Ohsweken, Ontario.

Mr. Riccio has over 20 years' experience in financial markets, with the majority of time spent in the mining industry. He most recently co-founded Vikara Capital that manages a liquid, digital assets fund. He was previously a Director at Macquarie Group in the Commodities and Global Markets Division in Sydney. Prior to Macquarie, he was a Director at commodities private equity firm Denham Capital in Perth and Houston and Vice President in the investment banking group at Merrill Lynch in Sydney and Los Angeles. He has co-founded a number of businesses including copper and nickel royalty company Nova Royalty. He holds a BS in Finance from University of Colorado Boulder, an MBA from University of Texas Austin and is a CFA Charterholder.

The Company also announces the resignation of Mr. Kevin Bottomley from his role of Director of the Company, effective immediately. The Company would like to thank Mr. Bottomley for his contributions during his tenure that helped guide the company through various strategic decisions.

President, CEO and director Rob Leckie comments "It is a pleasure to welcome Mr. Christmas and Mr. Riccio to our board of directors. Their experience and expertise will undoubtedly serve the interests of our shareholders in advancing our Nunavut project. I would also like to express my gratitude to Mr. Bottomley. His professionalism and insights were of great value to the board. We wish him continued success in his endeavours. On behalf of the company, I would like to thank all three individuals for their commitment to Future Fuels".

Grant of Stock Options

The Company also wishes to announce that it has granted (the "Grant") an aggregate of 4,380,000 incentive stock options (each, an "Option") to purchase up to 4,380,000 common shares of the Company (each, a "Share") to certain directors, officers and consultants under its Equity Incentive Plan. The Options are exercisable for a period of two years from the date of Grant, expiring on January 7, 2027, at a price of $0.44 per Share. The Options will vest immediately.

All Options and the Shares underlying such Options are subject to a hold period of four months and one day from the date of issuance.

About Future Fuels Inc.

Future Fuels' principal asset is the Hornby Uranium Project, covering the entire 3,407 km² Hornby Basin in north-western Nunavut, a geologically promising area with over 40 underexplored uranium showings. Additionally, Future Fuels holds the Covette Property in Quebec's James Bay region, comprising 65 mineral claims over 3,370 hectares. Future Fuels Inc. is publicly listed in Canada on the TSX Venture Exchange, under the symbol "FTUR," and in Germany on the Börse Frankfurt under the symbol "S0J" or WKN: A40TUW. You are invited to find out more at www.futurefuelsinc.com where you can subscribe for News Alerts, or follow us on Facebook, X.com or LinkedIn.

On behalf of the Board of Directors

FUTURE FUELS INC.

"Rob Leckie"
Rob Leckie, CEO
Tel: 604.681.1568
Email: info@futurefuelsinc.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:

This news release may contain "forward-looking statements" under applicable Canadian securities legislation. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward-looking statements in this news release include statements with respect to the future vesting dates respecting the Options. Forward-looking statements are subject to various known and unknown risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements, including risks related to factors beyond the control of the Company. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: Future Fuels Inc.



View the original press release on accesswire.com

© 2025 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.